3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
12
Carcinoma, Transitional Cell
7
Neoplasm Metastasis
5
Breast Neoplasms
5
Ureteral Neoplasms
4
Neoplasms
4
Urethral Neoplasms
2
Recurrence
2
Lung Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Urothelial Cancer
1
Urologic Neoplasms
1
Urogenital Neoplasms
1
Unspecified Adult Solid Tumor, Protocol Specific
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Renal Insufficiency
1
Prostatic Neoplasms
1
Penile Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Locally Advanced or Metastatic Unresectable Urothelial Cancer
1
Kidney Neoplasms
1
Carcinoma, Small Cell
1
Carcinoma
1
Breast Neoplasms, Male
1
Interventions
pembrolizumab
5
padeliporfin
5
Nivolumab
5
fludarabine
4
aldesleukin
4
Ipilimumab
4
Cyclophosphamide
4
atezolizumab
3
Specimen Handling
3
Paclitaxel
3
Magnetic Resonance Spectroscopy
3
Gemcitabine
3
Carboplatin
3
vedolizumab
2
olaparib
2
niraparib
2
motexafin gadolinium
2
cabozantinib
2
anlotinib
2
abiraterone
2
Therapeutics
2
Sunitinib
2
Standard of Care
2
Riluzole
2
Radiation Dose Hypofractionation
2
Prednisone
2
Pluvicto
2
Mitomycin
2
LDP-02
2
Infliximab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Urogenital Neoplasms
×
vinflunine
×
Clear all
NCT01599013
2015-12-08
JASINT1
Pierre Fabre Medicament
Phase 2
Completed
69 enrolled